These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21850242)

  • 1. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets.
    Martel CJ; Agger EM; Poulsen JJ; Hammer Jensen T; Andresen L; Christensen D; Nielsen LP; Blixenkrone-Møller M; Andersen P; Aasted B
    PLoS One; 2011; 6(8):e22891. PubMed ID: 21850242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes.
    Rosenkrands I; Vingsbo-Lundberg C; Bundgaard TJ; Lindenstrøm T; Enouf V; van der Werf S; Andersen P; Agger EM
    Vaccine; 2011 Aug; 29(37):6283-91. PubMed ID: 21722683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets.
    Cheng X; Zengel JR; Suguitan AL; Xu Q; Wang W; Lin J; Jin H
    J Infect Dis; 2013 Aug; 208(4):594-602. PubMed ID: 23656978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
    Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
    Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
    Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
    Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
    Diallo A; Victor JC; Feser J; Ortiz JR; Kanesa-Thasan N; Ndiaye M; Diarra B; Cheikh S; Diene D; Ndiaye T; Ndiaye A; Lafond KE; Widdowson MA; Neuzil KM
    Vaccine; 2018 Oct; 36(43):6424-6432. PubMed ID: 30224199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant.
    Christensen D; Christensen JP; Korsholm KS; Isling LK; Erneholm K; Thomsen AR; Andersen P
    Front Immunol; 2017; 8():1928. PubMed ID: 29358939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
    Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
    J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.
    Allen JD; Ray S; Ross TM
    PLoS One; 2018; 13(9):e0204284. PubMed ID: 30265682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
    J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
    Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
    J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.